Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/infusion-site-soft-tissue-injury-after-paclitaxel-administration-5e3rdiJlHh
References (14)
-
Robert Dorr (1990)
Antidotes to vesicant chemotherapy extravasations.Blood reviews, 4 1
-
(1993)
physicians and oncology -
R. Gregory, A. DeLisa (1993)
Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.Clinical pharmacy, 12 6
-
Practical guide to chemotherapy administration for physicians and oncology nurses -
E. Rowinsky, E. Eisenhauer, V. Chaudhry, S. Arbuck, R. Donehower (1993)
Clinical toxicities encountered with paclitaxel (Taxol).Seminars in oncology, 20 4 Suppl 3
-
R. Dorr, D. Alberts, A. Stone (1985)
Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse.Cancer treatment reports, 69 4
-
EJ Gallina (1993)
Cancer: principles & practice of oncology -
J. Ajani, Leslie Dodd, Karen Daugherty, Dawn Warkentin, D. Ilson (1994)
Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course.Journal of the National Cancer Institute, 86 1
-
WP Mcguire, E. Rowinsky, NB Rosenhein, F. Grumbine, D. Ettinger, D. Armstrong, RC Donehower (1990)
Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasmsInternational Journal of Gynecology & Obstetrics, 31
-
P. Wiernik, E. Schwartz, J. Strauman, J. Dutcher, R. Lipton, E. Paietta (1987)
Phase I clinical and pharmacokinetic study of taxol.Cancer research, 47 9
-
E. Rowinsky, V. Chaudhry, A. Forastiere, S. Sartorius, D. Ettinger, L. Grochow, B. Lubejko, D. Cornblath, R. Donehower (1993)
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 10
-
RT Dorr, DS Alberts (1983)
Skin ulceration potential without therapeutic anticancer activity for epidophyllotoxic commercial diluents, 1
-
NB Tsavaris, P Komitsopoulou, P Karagiaouris, I Loukatou, N Tzannous, N Mylonakis (1992)
Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach, 30
-
R. Donehower, E. Rowinsky, L. Grochow, S. Longnecker, D. Ettinger (1987)
Phase I trial of taxol in patients with advanced cancer.Cancer treatment reports, 71 12
- Publisher
- Wiley
- Copyright
- Copyright © 1995 Wiley Subscription Services
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- DOI
- 10.1002/1097-0142(19950701)76:1<116::AID-CNCR2820760118>3.0.CO;2-P
- Publisher site
- See Article on Publisher Site
Abstract
Background. Paclitaxel is a diterpenic plant product that has significant activity in several solid tumors, including epithelial ovarian cancer. After promising results in Phase I and II studies, its use has increased dramatically. With this increased use, isolated reports of local tissue reactions to paclitaxel have been described. The purpose of this study was to characterize further the presentation and clinical course of this toxic effect.
Journal
Cancer – Wiley
Published: Jan 1, 1995
Keywords: ; ; ;